Stock Alert: Eiger BioPharma Climbs 8%

(RTTNews) - Shares of Eiger BioPharmaceuticals, Inc. (EIGR) are climbing more than 8% Thursday morning after the company announced positive results from the study of its antiviral therapy in Covid-19 patients.

The study called ILIAD (Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in Covid-19)in outpatients with mild to moderate Covid-19 showed that the SARS-CoV-2 RNA viral load decline from baseline was significantly greater in the Lambda group than in the placebo group from day 5 on wards.

EIGR stock is currently trading at $9.35. It has traded in the range of $4.55- $15.82 in the last one year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More